Osteoporosis medication and exercise work on different halves of the same process, which is why they are complementary rather than either/or. Medication changes the biology of bone remodeling — slowing how fast old bone is removed, or stimulating new bone to form — while loading supplies the mechanical signal that tells bone where to add strength, and builds the muscle and balance that keep you off the floor in the first place.
How do osteoporosis medications actually work?
Bone is constantly being torn down and rebuilt, and osteoporosis treatments act on opposite ends of that cycle. Antiresorptives slow the removal side: that family includes the bisphosphonates, denosumab, and hormone-based options such as estrogen therapy and estrogen agonist/antagonists. Anabolics do the reverse — they stimulate the formation side, and include teriparatide, abaloparatide and romosozumab. Both families lower fracture risk, and as the Bone Fit™ clinical manual puts it plainly, there is no best medication for everyone: the choice depends on your baseline level of risk, other medical conditions, the goals of therapy, and your own preference. That choice belongs to your prescriber, made with you.
| Antiresorptive drugs | Anabolic drugs | Exercise | |
|---|---|---|---|
| What it does | Slows the removal of old bone | Stimulates new bone formation | Signals bone where to add strength |
| Includes | Bisphosphonates, denosumab, hormone-based options | Teriparatide, abaloparatide, romosozumab | Progressive resistance, impact, balance work |
| Where it acts | Throughout the skeleton | Throughout the skeleton | Mostly the sites you actually load |
| Muscle and balance | Not what these drugs act on | Not what these drugs act on | Strength, posture, balance, confidence |
| Who decides | Your prescriber | Your prescriber | You, with your physical therapist |
Do I still need to exercise if I'm taking medication?
Yes, and the reason is simple: no medication makes you stronger, steadier, or better at getting out of a chair. Most osteoporotic fractures happen during a fall, so strength and balance training protect you by a completely different route than a drug does. Guidance for people at high fracture risk — including Osteoporosis Canada's Too Fit To Fracture recommendations — treats medication, strength and balance exercise, and falls prevention as a package rather than a menu. The Bone Fit™ manual also makes a point worth sitting with: medication studies often show fairly small changes in bone density alongside much larger reductions in fracture risk. That is a useful reminder that the density number is not the only thing keeping a bone intact, and that your training is doing work no scan will ever show.
Is exercise as good as medication?
Nobody can answer that honestly, because the two have not been compared head to head for fracture outcomes. Drug trials are large and built to count broken bones; exercise trials are smaller and usually measure bone density, strength, and function. What we can say is what the LIFTMOR trial found: in 101 postmenopausal women with low bone mass, mean age 65, eight months of supervised twice-weekly high-intensity training raised lumbar-spine bone density by 2.9% while the control group lost 1.2%. At the femoral neck, the training group gained 0.3% against the control group's 1.9% loss — a between-group difference that mostly reflects holding ground, not a large hip gain. LIFTMOR compared exercise with usual care; it was not designed to measure exercise added on top of a medication, so it cannot tell you how the two sum. The researchers are also explicit that they do not recommend replicating the protocol unsupervised.
Why does stopping a bone medication matter?
Because these drugs do not all behave the same way when they are stopped. Bisphosphonates bind into bone tissue and their effect lingers after the last dose, which is why prescribers sometimes plan a break in treatment. Denosumab is different: its prescribing information and the Endocrine Society's clinical practice guideline both warn that its effect fades relatively quickly, so stopping it — or letting a dose run late — without moving to another antiresorptive has been linked to rapid bone loss and, in some people, multiple spinal fractures. Anabolic treatment is given as a limited course and is usually followed by an antiresorptive to hold on to what was gained. The pattern behind all three is the same: what happens next is a sequencing decision, and it belongs to the person who prescribed it.
Does being on medication change how I should train?
Not in the way people hope. Medication does not make a fragile vertebra safe to load into forward bending, so the movement precautions stay exactly as they were: no loaded, end-range spinal flexion, rotation, or side-bending, and care with impact. Bone Builder makes that call from your fracture history, your T-score, and whether you are in pain right now — not from your prescription. If you screen as higher risk, the program swaps flagged movements for neutral-spine work like Bird Dog, keeps loading gentle with Heel Drops rather than a Box Jump, and builds Hip Hinge Practice long before it builds a Barbell Deadlift. Being on treatment is not a shortcut to heavier loads; technique earns those.
What should I ask the person who prescribes it?
- What is my fracture risk, and does it warrant medication in the first place?
- Which family is this one — antiresorptive or anabolic — and how long is the planned course?
- What is the plan for when I stop, and how will we protect what I have gained?
- Are my calcium and vitamin D adequate for this medication to work well? (the daily targets are here)
- Do I have any exercise restrictions you want my physical therapist to know about?